STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans

Aurora Therapeutics, a startup focused on building personalized gene-editing drugs, has scrapped its lead program and slashed staff, just seven months after it launched, STAT has learned.  A company spokesperson declined to say how many employees were laid off, or whether any of the startup’s three-person leadership team would stay on. Aurora’s chief scientific officer left the company this year.  The company appears to have been undercut by Beam Therapeutics, a larger and more established compe...